Skip Navigation

Europace 2005 7(6):546-553; doi:10.1016/j.eupc.2005.05.017
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sticherling, C.
Right arrow Articles by Zabel, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sticherling, C.
Right arrow Articles by Zabel, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 The European Society of Cardiology. Published by Elsevier Ltd. All rights reserved.

Comparison of acute and long-term effects of single-dose amiodarone and verapamil for the treatment of immediate recurrences of atrial fibrillation after transthoracic cardioversion

Christian Sticherlinga,*, Steffen Behrensb, Wolfram Kamkec, Annett Stahnd and Markus Zabeld

aDepartment of Cardiology, University Hospital Basel Petersgraben 4, 4031 Basel, Switzerland; bDepartment of Cardiology, Vivantes Humboldt-Klinikum Berlin, Germany; cDepartment of Cardiology, Spreewald Hospital Burg, Germany; dDepartment of Cardiology, Charite-University Hospital Benjamin Franklin Berlin, Germany

AIMS: Amiodarone and verapamil have been employed to treat immediate recurrences of AF (IRAF) after cardioversion. This study compares the efficacy of these agents for the treatment of IRAF.

METHODS AND RESULTS: One hundred and eighty-five patients underwent transthoracic cardioversion (CV) for AF. AF recurred within 10 min in 20 patients (10.8%). These patients were randomized to verapamil (seven patients), or amiodarone (13 patients). After administration of verapamil and repeat CV, five patients (71%) experienced IRAF, compared with seven patients (54%) receiving amiodarone (P = 0.4). Including the results after crossover, IRAF occurred in 8/10 patients (80%) who received verapamil, compared with 7/15 patients (47%) who received amiodarone (P = 0.1). The combination of these agents prevented IRAF in 10/20 patients (50%). After a follow-up of 319 ± 189 days, 42% of the IRAF patients treated with verapamil and/or amiodarone remained in sinus rhythm, which did not differ from patients without IRAF (53%, P = 0.7).

CONCLUSIONS: IRAF occurs in 10% of patients undergoing CV. Amiodarone and verapamil are effective in preventing IRAF and result in a sinus rhythm maintenance rate of 50%. Since there is no difference in the long-term maintenance of sinus rhythm between patients with and without IRAF, attempts to restore sinus rhythm after pharmacological pretreatment are justified.

Key Words: atrial fibrillation, cardioversion, verapamil, amiodarone

*Corresponding author. Tel.: +41 61 265 5214; fax: +41 61 265 4598. E-mail address: csticherling{at}uhbs.ch(C. Sticherling)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.